Oliver G Ottmann

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. request reprint
    Ottmann O, Druker B, Sawyers C, Goldman J, Reiffers J, Silver R, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965-71 pubmed
    ..Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib. ..
  2. request reprint
    Ottmann O, Bug G, Krauter J. Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia. Semin Hematol. 2007;44:183-92 pubmed
    ..Selection of those patients likely to benefit from growth factors in a specific clinical setting is a worthwhile endeavour. ..
  3. request reprint
    Bruck P, Wassmann B, Lopez E, Hoelzer D, Ottmann O. Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms. Leuk Res. 2004;28:1153-7 pubmed
    ..SNPs of PDGFR genes do not appear to play a role in patient's susceptibility to clinically severe edema formation during treatment with STI571. ..
  4. Ottmann O, Pfeifer H. First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol. 2009;21 Suppl 1:S43-6 pubmed publisher
    ..Following SCT, the pre-emptive use of imatinib appears to reduce the relapse rate. Novel immunotherapeutic interventions and combinations of TKI are also being explored...